Clinical Trials · NCT06640972
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Response Pharmaceuticals
- Enrollment
- 68
- Start date
- Sep 2024
- Locations
- 1 site, United States
- Primary endpoint
- Triglycerides